论文部分内容阅读
新的大环内酯类免疫抑制剂FK506是一种强力的选择性抗T细胞药物,其作用方式与环孢菌素(CS)相同。肝移植受体的临床研究表明,FK506的危险/受益比率低于CS。目前欧洲及北美在器官移植的受体中正在进行FK506的多中心前瞻性对照研究。 CS与FK506 CS是用于器官移植患者的主要免疫抑制剂,虽然在过去10年中在提高人的器官移植疗效上起了积极作用,但其对肾的毒性作用可引起肾移植患者及肾功能正常的心或肝移植患者的肾功能损害。此外,免疫抑制剂正在日益广泛地用于治疗自身免疫性疾病,因此有必要寻求一种安全的免疫抑制剂。FK
The new macrolide immunosuppressant FK506 is a potent and selective anti-T-cell drug that acts in the same way as cyclosporine (CS). Clinical studies of liver transplant recipients have shown that the risk / benefit ratio of FK506 is lower than that of CS. At present, multi-center, prospective, controlled studies of FK506 are underway in recipients of organ transplantation in Europe and North America. CS and FK506 CS, the primary immunosuppressive agents used in organ transplant recipients, have played a positive role in improving the efficacy of organ transplantation in humans over the past decade but their toxic effects on the kidney can cause kidney transplant recipients and renal function Renal impairment in normal heart or liver transplant patients. In addition, immunosuppressive agents are increasingly used to treat autoimmune diseases, so it is necessary to find a safe immunosuppressant. FK